NCT06145724 EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis (Aim 1)
| NCT ID | NCT06145724 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Columbia University |
| Condition | Maternal Sepsis |
| Study Type | INTERVENTIONAL |
| Enrollment | 33,183 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 33,183 participants in total. It began in 2025-06-01 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Sepsis is the second leading cause of maternal death in the U.S. Labor and postpartum are particularly vulnerable risk periods. The goal of this multi-center, multidisciplinary study is to evaluate a maternal sepsis safety bundle.
Eligibility Criteria
Inclusion Criteria: Birthing Person (EMR evaluation): -Delivery hospitalizations and associated postpartum readmissions at the 4 hospital sites between 2020-2025 Exclusion Criteria: Birthing Person (EMR evaluation) -Delivery hospitalizations (and associated postpartum readmissions)to a hospital other than the 4 hospital sites or outside of 2020-2025 timeframe
Contact & Investigator
Dena Goffman, MD
PRINCIPAL INVESTIGATOR
Columbia University
Frequently Asked Questions
Who can join the NCT06145724 clinical trial?
This trial is open to female participants only, studying Maternal Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06145724 currently recruiting?
Yes, NCT06145724 is actively recruiting participants. Contact the research team at br2724@cumc.columbia.edu for enrollment information.
Where is the NCT06145724 trial being conducted?
This trial is being conducted at New York, United States, New York, United States, New York, United States, The Bronx, United States.
Who is sponsoring the NCT06145724 clinical trial?
NCT06145724 is sponsored by Columbia University. The principal investigator is Dena Goffman, MD at Columbia University. The trial plans to enroll 33,183 participants.